The Justice Department signed a deferred prosecution agreement 15 months ago with California biotech company InterMune regarding ex-employees who had engaged in illegal off-label marketing of its osteoporosis drug Actimune. The agreement didn't protect the former executives from prosecution, but the DOJ has seldom gone criminal against executives from other pharma companies that have settled. Now, in a rare turn of events, lawyers close to the InterMune case say charges against the executives are likely.
January 25, 2008 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Scott Harkonen may have thought he could move on.
Fifteen months ago, the Department of Justice signed a deferred prosecution agreement with InterMune, the company Harkonen once led. Some former employees of the Brisbane, Calif.-based biotech had engaged in illegal off-label marketing of its osteoporosis drug Actimune, the company acknowledged.
Presented by BigVoodoo
Consulting Magazine identifies the best firms to work for in the consulting profession.
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
Women, Influence & Power in Law Awards honors women lawyers who have made a remarkable difference in the legal profession.
Litigation defense commercial casualty/complex catastrophic cases. Flexible schedule with work in Philadelphia, Conshohocken, and/or remot...
Our close client, an electric cooperative, is seeking to hire a Vice President General Counsel to lead its legal function. Hired attorney ...
POSITION SUMMARY The United States District Court for the District of New Jersey is seeking a Temporary Law Clerk for the period December 16...
